Inventor
Yao-Ling Qiu
Inventor
Andover, MA, US
Overview
Patents· 69 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Dprimary
C07DHeterocyclic compounds25%
A61KPreparations for medical, dental or toiletry purposes23%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations23%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium11%
C07HSugars10%
C12NMicroorganisms or enzymes5%
C07CAcyclic or carbocyclic compounds2%
C07BGeneral methods of organic chemistry1%
Y02ATechnologies for adaptation to climate change1%
PatentTitleYear
10,752,611Benzimidazole derivatives202010,738,035Hepatitis B antiviral agents202010,729,688Hepatitis B antiviral agents202010,723,733Hepatitis B antiviral agents202010,702,528Hepatitis B antiviral agents202010,640,511Hepatitis B antiviral agents202010,538,532Hepatitis B antiviral agents202010,442,788Hepatitis B antiviral agents201910,428,070Hepatitis B antiviral agents201910,407,445Hepatitis C virus inhibitors201910,301,255Hepatitis B antiviral agents201910,280,175Hepatitis B antiviral agents201910,189,846Hepatitis B antiviral agents201910,179,131Hepatitis B antiviral agents201910,179,792Hepatitis B antiviral agents201910,017,499Benzimidazole derivatives20189,765,087'Benzimidazole derivatives'20179,732,110'Nucleoside and nucleotide derivatives'20179,676,802'Hepatitis C virus inhibitors'20179,675,632'Nucleoside and nucleotide derivatives'20179,156,818'Hepatitis C virus inhibitors'20159,127,021'Hepatitis C virus inhibitors'20159,085,599'2′allene-substituted nucleoside derivatives'20159,060,971'Combination pharmaceutical agents as inhibitors of HCV replication'20159,000,020'Linked dibenzimidazole antivirals'20158,933,110'Hepatitis C virus inhibitors'20158,927,739'Processes for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives'20158,927,709'Hepatitis C virus inhibitors'20158,921,573'Processes for the preparation of novel benzimidazole derivatives'20148,822,700'Hepatitis C virus inhibitors'20148,815,928'Hepatitis C virus inhibitors'20148,785,487'Hepatitis C virus inhibitors'20148,778,938'Hepatitis C virus inhibitors'20148,759,332'Hepatitis C virus inhibitors'20148,703,938'Hepatitis C virus inhibitors'20148,697,704'Hepatitis C virus inhibitors'20148,673,954'Benzimidazole derivatives'20148,653,070'Hepatitis C virus inhibitors'20148,637,561'Linked diimidazole derivatives'20148,609,648'Hepatitis C virus inhibitors'20138,507,522'Hepatitis C virus inhibitors'20138,420,686'Linked diimidazole antivirals'20138,354,383'6,11-bridged biaryl macrolides'20138,314,135'Linked dibenzimidazole antivirals'20128,273,720'6,11-bicyclolides: bridged biaryl macrolide derivatives'20128,242,156'Linked dibenzimidazole derivatives'20128,221,737'Hepatitis C virus inhibitors'20128,188,132'Linked dibenzimidazole derivatives'20128,163,707'4′-allene-substituted nucleoside derivatives'20128,101,643'Benzimidazole derivatives'20127,919,627'Processes for the preparation of hydroxylamines'20117,622,452'C-9 alkenylidine bridged macrolides'20097,538,225'Processes for the preparation of o-(6-pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine'20097,402,568'Bicyclic 9a-azalide derivatives'20087,273,853'6-11 bicyclic ketolide derivatives'20077,265,094'9N-substituted 6-11 bicyclic erythromycin derivatives'20077,129,221'6,11-bicyclic erythromycin derivatives'20067,064,110'6-11 bicycle ketolide derivatives'20066,958,345'2-hydroxymethylcyclopropylidene methylpurines and -pyrimidines as antiviral agents'20056,878,691'6-11 bicyclic ketolide derivatives'20056,790,835'Bicyclic macrolide derivatives'20046,790,841'2-hydroxymethylcyclopropylidenemethylpurines and -pyrimidines as antiviral agents'20046,774,115'6-O-substituted bicyclic ketolides'20046,765,016'Bicyclic ketolide derivatives'20046,753,415'23-O-substituted 5-O-mycaminosyltylonide derivatives'20046,716,820'6-O-substituted bicyclic macrolides'20046,710,034'5-O-mycaminosyltylonide derivatives'20046,576,615'4-O-substituted tylosin analogs'20036,352,991'2-hydroxymethylcyclopropylidenemethylpurines and -pyrimidines as antiviral agents'2002Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2002–2004Based in Detroit, MI, US· patent location history
2003–2020Patents assigned to ENANTA PHARM INC (66)· patent assignee history
2003–2004Based in Somerville, MA, US· patent location history
2004–2020Based in Andover, MA, US· patent location history
2005Based in Hamburg, PA, US· patent location history
2012–2015Patents assigned to OR YAT SUN (27)· patent assignee history
2012–2015Patents assigned to QIU YAO-LING (27)· patent assignee history
2012–2015Patents assigned to PENG XIAOWEN (23)· patent assignee history
2012–2015Patents assigned to WANG CE (23)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| ENANTA PHARM INC | 66 | 2003–2020 |
| OR YAT SUN | 27 | 2012–2015 |
| QIU YAO-LINGself | 27 | 2012–2015 |
| PENG XIAOWEN | 23 | 2012–2015 |
| WANG CE | 23 | 2012–2015 |
Locations
| Location | Patents | Span |
|---|---|---|
| Andover, Massachusetts, US | 63 | 2004–2020 |
| Somerville, Massachusetts, US | 3 | 2003–2004 |
| Detroit, MI, US | 2 | 2002–2004 |
| Hamburg, Pennsylvania, US | 1 | 2005 |